More recently, the FDA posted two two letters: one backdated for September 9, regarding GSK’s HIV medication Apretude and one ...

Phase 3 studies point to sustained disease control in patients who remain symptomatic despite standard therapies.

BestMediaInfo.com tracks last week’s major leadership appointments, promotions, and exits impacting the world of advertising, ...

As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review. The Medicines and Healthcare products ...

With a fresh endorsement from the FDA, the last of five major drug approvals has fallen into place for GSK in 2025. | On ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

FDA approves GSK's Exdensur for severe eosinophilic asthma, backed by Phase 3 data showing up to 58% fewer asthma attacks ...

GSK (GSK) stock is in focus as an expert panel of the European Medicines Agency ((EMA)) endorses the company's Arexvy RSV ...

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

Rival European pharma giants Sanofi and GSK have both forged new partnerships to bolster their preclinical research. | Rival ...